home · filing · 0001193125-21-290938
8-K filed October 4, 2021, 7:59 PM ET
ticker ANNX
CIK 0001528115
leadership
confidence high
sentiment positive
materiality 0.55
Annexon promotes Yednock to CIO, hires Mattheakis as CSO
Annexon, Inc.
Ted Yednock, formerly CSO since 2013, promoted to Chief Innovation Officer effective immediately.
Larry Mattheakis appointed Chief Scientific Officer; previously SVP at Protagonist Therapeutics.
Yednock remains on executive committee, chairs Scientific Advisory Board; focus on C1q platform expansion.
Mattheakis brings drug discovery experience; company has three clinical-stage candidates in seven trials.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Role change
Ted Yednock
Chief Innovation Officer
Effective 2021-09-30
Filed October 4, 2021, 7:59 PM ET
appointed Ted Yednock, Ph.D. as Chief Innovation Officer
Appointed
Larry Mattheakis
Chief Scientific Officer
Effective 2021-09-30
Filed October 4, 2021, 7:59 PM ET
Larry Mattheakis, Ph.D. as Chief Scientific Officer
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
Ted Yednock was appointed as Chief Innovation Officer at Annexon, Inc..
Action appointed
Role Chief Innovation Officer
Exact text from the filing
appointed Ted Yednock, Ph.D. as Chief Innovation Officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Larry Mattheakis was appointed as Chief Scientific Officer at Annexon, Inc..
Action appointed
Role Chief Scientific Officer
Exact text from the filing
Larry Mattheakis, Ph.D. as Chief Scientific Officer
View on SEC.gov
Source: SEC EDGAR
accession 0001193125-21-290938
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.